PHP64 THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM  by Mauskopf, J. et al.
OBJECTIVES:TheNational List of Health Services (NLHS) in Israel has been updated
annually since 1999 but results from economic evaluations (EE) were not used to
support coverage decisions. We explored the potential availability of EE results to
the committee responsible for updating the NLHS at the times of coverage deci-
sions and whether availability and use of these data could have altered these
decisions. METHODS: We used the Tufts Medical Center Cost-Effectiveness Anal-
ysis Registry (http://www.cearegistry.org) to search for relevant cost/QALY EE for
all drugs and their relevant indications added to the NLHS from 1999 through 2008.
For each pair of drug and cost/QALY publication we recorded the publication date,
the intervention(s) and comparator(s) considered and the incremental cost-effec-
tiveness ratio (ICER) to determine value for money. Based on available ICERs we
qualitatively classified each coverage decision into one of three categories: 1)The
coverage decision can be justified on EE grounds (EE suggest the drug is either
dominant/cost-saving or provides good value for money); 2)The coverage decision
cannot be justified on EE grounds; 3)The evidence from EE is mixed and we could
not determine whether the coverage decision can be justified or not. RESULTS:
Relevant cost/QALY analyses were found for 181(40%) of 451 drugs included in the
updates of the NLHS of which only 71 (16%) of drugs had relevant EE prior to the
coverage decision. Based on the evidence gathered from EE prior to and following
the coverage decision, we suggest that decisions were correct in 56% of the cases,
incorrect in 17% and ambiguous in 27%. CONCLUSIONS: The use of EE to support
coverage decisions could have altered decisions in a sizable proportion of drugs
added to the NLHS in Israel. Avoiding the use of results from EE to support public
funding of drugs may lead to a non-optimal use of scarce healthcare resources.
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ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING
AND MARKET ACCESS
Grosvenor A, Saraf S, Jones K
PriceSpective Ltd., London, UK
OBJECTIVES: Orphan drug (OD) legislation has been highly successful in incentiv-
ising pharmaceutical companies to invest in developing medicines for previously-
ignored rare diseases. Since 2005, a third of all new drug approvals in the US have
been ODs, and worldwide the market is forecast to grow at a CAGR of 6%, reaching
$112bn in 2014. Although these products still only account for 2-3% of total drug
budgets in the US and EU, their burgeoning number is placing increased pressure
on funding. This poster aims to explore how payers in the US and EU are respond-
ing to these financial demands. METHODS: We reviewed all ODs approved in the
US and EU since 1st January 2000 and, for each, calculated the average cost per
patient per year, based on public prices in the US and 5EU. We also reviewed
published payer assessments of these products, and all government proposals
regarding OD policies since 2005. RESULTS: Since 2007, there has been an obvious
drop in prices secured for novel ODs. In the EU alone, the average cost per patient
per year for products approved in 2008 to 2010 (€34,890) is 73% lower than for those
approved in 2000 to 2007 (€129,228). Furthermore, our analysis suggests payers are
adopting a more discerning approach to the way they evaluate orphan drugs, es-
pecially those perceived to be exploiting the original intent of the legislation. For
example, Germany’s recent healthcare reforms highlighted plans to target ODs
that fail to demonstrate meaningful patient benefits, such as survival, and all ODs
exceeding annual sales of €50m will have to submit a cost-benefit analysis.
CONCLUSIONS: Payers are clamping down on “opportunistic” ODs and only those
with a robust body of evidence supporting both the clinical and economic argu-
ments for their use will secure favourable pricing and market access.
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WIDER CONSULTATION IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
DECISIONS: BETTER UNDERSTANDING OR A LOBBYING OPPORTUNITY?
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OBJECTIVES: HTA agencies worldwide have varying processes that allow consul-
tation with stakeholders during decision-making. The objective of this study is to
determine the impact of the National Institute for Health and Clinical Excellence
(NICE) Single Technology Appraisal (STA) consultation stage on reimbursement
decisions of pharmaceuticals. METHODS: Documentation was accessed from the
NICE website for all STA’s conducted between 2006 and August 2010. Details of the
first Appraisal Consultation Document (ACD) draft decision, subsequent ACDs,
Final Appraisal Determination (FAD) and final guidance decision were extracted.
The decisions were categorised with respect to the licensed indication (recom-
mended, restricted, not recommended, only in research). Details of the further
analysis and evidence submitted by the manufacturer as a result of consultation
were extracted. These data were analysed for the different stages of
decision-making. RESULTS: The website search identified 55 NICE appraisals of
which over fifty percent were for cancer medicines. Final decisions (draft first
provisional decision) included 36% (13%) recommended, 36% (20%) restricted deci-
sion, 16% (56%) not recommendeddecision and 11% (11%) terminated decision. One
appraisal contained only in research recommendations in addition for use in rou-
tine practice. An ACDwas produced in 42 appraisals, followed by themanufacturer
providing further economic analysis in 26 appraisals, a patient access scheme in 5
appraisals and new clinical evidence in 2 appraisals. Types of further economic
analysis provided by the manufacturer were for other treatments/strategies; dif-
ferent modelling assumptions; alternative survival distributions; further sensitiv-
ity analysis; and other. CONCLUSIONS: NICE’s iterative consultation process al-
lows consideration of evidence and wide consultation with stakeholders. This
results in evidence that is more appropriate for the evaluation of pharmaceutical’s
and partly explains the higher recommendation rate when compared with similar
international reimbursement agencies. There is a need for further research to un-
derstand the impact of the different processes employed across countries’ deci-
sion-making.
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WHAT IS THE IMPACT OF COMPARATIVE EFFECTIVENESS AND VALUE BASED
PRICING ON A PRODUCT’S VALUE AND MARKET ACCESS?
Walker R, Ng-Haing J, Koruth R, Sparrowhawk K
PriceSpective, London, UK
OBJECTIVES: Comparative effectiveness (US) and value-based pricing (VBP) (UK)
are anticipated to bring changes froma ‘free-pricing’ system for drugs to onewhere
prices are influenced by governmental authorities. A product’s value will take into
account additional factors, such as wider societal benefits and therapeutic innova-
tion. The aim of this research is to determine the impact of comparative effective-
ness and VBP on the price and market access of new drugs in depression.
METHODS:A literature reviewwas conducted using electronic databases (Medline,
Embase, Google Scholar). The search was performed for the years 2009-2011 and
key terms included comparative effectiveness USA, value based pricing UK, drug
value and societal benefits. In addition, an analysis of a UK Department of Health
consultation paper and the US Agency for Healthcare Research and Quality policy
documents was performed in order to determine how comparative effectiveness
and VBP may affect the market access and commercial viability of products in
disease area of depression (SSRIs, SNRIs and atypical antidepressants). A spread-
sheet was used to capture data and a comparison was undertaken to compare and
contrast the twomarkets and the different implications. RESULTS: The addition of
comparative effectiveness and VBP are to take account of indirect costs associated
with all disease areas. Depression has high indirect associated costs associated
and, as such, the value of novel antidepressants will increase. This is likely to
enable better access to new products. CONCLUSIONS: The move to comparative
effectiveness and VBP is likely to change the market access of products, particu-
larly in certain disease areas. There will be more positive drivers for investment in
the disease area of depression. Moreover, decisions taken at themargin during the
drug development processwill be impacted as any change inmarket access is likely
to affect the ‘Go/No go’ decision criteria.
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WHAT INFLUENCES PHARMACEUTICAL REIMBURSEMENT DECISIONS? A
SYSTEMATIC REVIEW OF FACTORS REPORTED TO INFLUENCE DECISIONS IN
OECD COUNTRIES
Bending MW1, Hutton J1, McGrath C2, Glanville J1
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OBJECTIVES: Many factors influence pharmaceutical reimbursement decisions.
This study aims to determine the influence of factors considered in the evaluation
of pharmaceuticals on the reimbursement decisions of government funded bodies
in OECD countries. METHODS: A search of MEDLINE, EMBASE, EconLit, Health Man-
agement Information Consortium, NHS EED and REPEC Economic working papers until
July 2010 was conducted. A hand search of the International Journal of Technology
Assessment in Health Care was undertaken (1990-2010). The following study de-
signs were eligible: experimental, quasi-experimental, retrospective, prospective,
case series and surveys or questionnaires design. The influential factors were re-
viewed across and within OECD countries. RESULTS: The search identified 12
quantitative studies and 23 qualitative studies. The quantitative studies consid-
ered the correlation between factors and decisions either through regression anal-
ysis of retrospective decisions or discrete choice experiments. Cost-effectiveness
was found to be consistently influential for reimbursement decision-making in
Australia, England, Canada and The Netherlands. There was variation in the defi-
nition of clinical considerations and other factors in studies conducted in coun-
tries. This limited comparability within and across countries. Studies reported
mixed evidence of the influence of the quality, quantity and type of clinical evi-
dence, robustness of economic models, sensitivity analysis, budget impact, lack of
alternative therapy and severity of disease on reimbursement decisions. Qualita-
tive studies reported narrative descriptions, case studies and interviews with de-
cision-makers. These studies supported the influence of cost-effectiveness found
in the quantitative evidence. They additionally described the influence of the com-
position of the decision panel, committee deliberations, stakeholder involvement
and lobbying on decisions. CONCLUSIONS: There is limited evidence on the influ-
ence of evaluation factors on reimbursement decisions in a few OECD countries
with established reimbursement processes. Wider investigation of the factors in-
fluential in other countries would allow comparison of the similarities and differ-
ences across OECD countries.
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DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM
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OBJECTIVES: In this paper we estimate the relationship between the financial im-
pact of a new drug on the health care system in Australia and the probability of the
drug being recommended for reimbursement by the Pharmaceutical Benefits Ad-
visory Committee (PBAC).METHODS: Data in the PBAC summary database regard-
ing drug-reimbursement decisions made between July 2005 and November 2009
were abstracted. Financial impact was categorized as A$0 or less, greater than A$0
up through A$10 million, and greater than A$10 million per year. Descriptive anal-
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ysis, logistic analysis, survival analysis, and recursive partitioning decision analy-
sis were used to estimate the relationship between the financial impact of a new
drug indication and the probability of its reimbursement. The multivariable anal-
yses controlled for other clinical and economic variables that have been shown to
be correlatedwith the probability of reimbursement, including the cost per quality-
adjusted life-year gained. RESULTS: In all analyses, financial impact was a signif-
icant predictor of the probability of reimbursement. For example, in the logistic
analysis, the odds ratio of reimbursement for a drug submission with a financial
impact greater than A$10 million compared with A$0 or less was 0.12 (95% confi-
dence interval [CI]: 0.03-0.55); the odds ratio of reimbursement for a drug submis-
sion with a financial impact greater than A$0 up through A$10 million compared
with A$0 or less was 0.16 (95% CI: 0.04-0.60). Similar results were obtained in the
survival analysis. In the recursive partition decision analysis, the first split of the
data was for submissions with a positive financial impact compared with those
with a negative financial impact. CONCLUSIONS: In Australia, financial impact on
the health care system is an important determinant of whether a new drug is
recommended for reimbursement, even when cost-effectiveness estimates and
other clinical and economic variables are controlled.
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HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR CELLULAR THERAPIES
AND REGENERATIVE MEDICINES: LESSONS FROM A HEALTH TECHNOLOGY
ASSESSMENT AND REIMBURSEMENT ANALYSIS IN THE UNITED STATES
Faulkner EC, Spinner DS
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Cellular therapies and regenerativemedicines, are poised to have the
same paradigm-shifting influence on healthcare as monoclonal antibodies (mABs)
and personalizedmedicine.While these therapies hold similarities to conventional
biopharmaceuticals, they also differ in material ways including attributes of both
medical devices and pharmaceuticals; use of multiple procedures to prepare and
deliver cells; and the potential to cure some diseases. Because of their complexity,
these technologies are also anticipated to be costly and face heavy scrutiny of
value. The objective of this research is to evaluate recent reimbursement policies
on regenerative medicines, compare them to current biopharmaceuticals, and
evaluate lessons for health economics and outcomes research (HEOR) and reim-
bursement planning. METHODS: A search of US HTAs from the Centers for Medi-
care and Medicaid Services, the Agency for Healthcare Research and Quality
(AHRQ), the BlueCross BlueShield Technology Evaluation Center and publicly avail-
able commercial payer coverage policieswas conducted to identify reimbursement
recommendations and supporting rationale. A review of the literature, including
the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement issues associated with regen-
erative medicines. RESULTS: Although a nascent treatment area, over 15 technol-
ogy assessments and coverage policies on regenerative medicines were available
from US HTA agencies and payers. Different from most other technologies, some
noncoverage positions have been established prior to the emergence of specific
technologies or supporting evidence. The literature relevant to HEOR issues on
regenerativemedicines is particularly limited to date. CONCLUSIONS:While payer
policies on regenerativemedicines reflected decision factors commonly associated
with biopharmaceuticals, other factors beyond conventional biologics were iden-
tified. These factors include special evidentiary considerations for cell processing
steps, influence of the evidence-base supporting multi-procedural steps on reim-
bursement, and evaluation of the entire procedure vs. the biopharmaceutical
alone. Key considerations for HEOR are discussed.
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DEMONSTRATING “DISEASE MODIFYING THERAPIES”? AN HTA PERSPECTIVE
McDonald P, Colasante W, Oshinowo B, Saraf S
PriceSpective Ltd., London, UK
OBJECTIVES: The objective of this study was to understand what stakeholders in
US, EU5, Canada & Australia interpret as disease modification. In chronic progres-
sive conditions, disease modification versus symptom control is the ultimate goal
of healthcare specialists. However, there is no consensus on what “disease modi-
fication” really is. From a HTA perspective, not only is there is difficulty in valuing
disease modifying interventions, but also implied risk to payers approving to re-
imburse these drugs at launch.METHODS: Primary research was undertaken with
payers and medical specialists to understand requirements to support disease
modification claims in HTA assessments. Various attributes were assessed during
in-depth discussions and through discrete choice conjoint. Over 100 respondents
were interviewed. RESULTS: The results show that that efficacy is themost impor-
tant attribute considered in disease modification for HTA assessments. The corre-
lation of biomarkers to clinical endpoints also has utility. The market access im-
plications for such products across geographies vary considerably. However, cost-
effectiveness remains a key driver in specific markets. CONCLUSIONS: Disease
modificationmeans delaying or halting the progression of a disease. Efficacy is the
most important single factor, with the evidence of magnitude and duration of
effect both being essential. However, efficacy alone is insufficient to support a
diseasemodification claim. Robust long termdata are also required and data show-
ing a meaningful improvement over currently available therapies. For regulators
and payers, acceptance of a diseasemodification claimmeans that payers take the
risk of reimbursing based on some extrapolation of data at launch. A commitment
to integrate a process of data review of outcomes over time linked with perfor-
mance will ensure any risk is mitigated.
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UNDERSTANDING THE VIETNAMESE PRICING AND REIMBURSEMENT
ENVIRONMENT THROUGH A COMPARISON WITH THAT OF CHINA
Lewis S, Dummett H
Double Helix Consulting, London, UK
OBJECTIVES: Vietnam is an emerging pharmaceutical market that is both poorly
understood and undergoing significant change, with a target for introducing uni-
versal healthcare by 2014. The objective of the research was to place Vietnam’s
pricing and reimbursement environment in a context that brings its dynamics into
clearer focus and to gauge the likely future direction of its evolution.METHODS: A
comparison with its neighbour, China, was conducted based on interviews in both
markets with government advisers, health economists and health policy profes-
sors, as well as KOLs. A comparative analysis was then conducted of the market
access dynamics and drivers, as well as of policy reform plans. RESULTS: Many
similarities exist between the P&R environments of the twomarkets, although they
sit at different places along the P&R development continuum. In both, branded
drugs enjoy a considerable price premium over generics, which could be as high as
40 times in Vietnam. However, China is looking to change the situation by remov-
ing the premium for off-patent branded drugs. Despite efforts in to develop their
reimbursement system, direct-sale to hospitals is the primary revenue channel for
pharmaceuticals, with KOL-endorsement amajormarket access driver. In terms of
drug price regulation, the most commonly used measure is through the enforce-
ment of price caps. CONCLUSIONS: The Vietnamese P&R system is similar to that
of China 5-10 years ago. Several fundaments in terms the structure of the health
system, formalisation of the reimbursement system andmarket access drivers are
the same, but China is significantly further down the line than its neighbour. How-
ever, the health reform agendas of the two markets are both heading in similar
directions.
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THE 15 YEARS EXPERIENCE OF NEW DRUGS ADOPTION AND REIMBURSEMENT
IN TAIWAN’S NATIONAL HEALTH INSURANCE
Huang WF1, Hsieh CF1, Chen GT2
1National Yang-Ming University, Taipei, Taiwan, 2Koo Foundation Sun Yat-Sen Cancer Center,
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OBJECTIVES: To present the empirical experience of new drug listing and reim-
bursement under Taiwan’s National Health Insurance (NHI), and to discuss the
performance of such mechanism. We also attempt to assess its impact on the
public access to pharmaceutical innovations. METHODS: The materials are based
on the documentation of Taiwan’sNHIDrug ReviewCommittee (DRC) over 15 years
period (19962010). We defined the criteria of pricing methods into 9 categories:
International Price Comparison, Comparison with Similar Products with Equiva-
lent Therapeutic Effects, Price Proportion Method, Price Addition, Orphan Drugs,
The Lowest Available International Price, Cost Analysis, Grouping and Others in-
cluded risk sharing managements. RESULTS: The total number of new drugs that
applied for NHI listing and reimbursement during 19962010 was 1103, and the
number of petition cases was 587(53%). The total number of new drugs with final
pricing decisions in this study was 802. Among them, 343 items were issued with
reimbursement pricewithout petition, and the remaining new drugs received their
reimbursement prices after petition on initial pricing decisions. The approved price
was averaged 69% of the international median prices, and was only 60% of inter-
national median prices among petition cases. The top threemethods of pricing are
Price Proportion Method, Equivalent Therapeutic Effect with Similar Product
(23.5%), and International Price Comparison. Because NHI faced financial crisis in
the past 10 years, the price of reimbursement came as approximately 70% of their
respective application prices in the recent years. More and more risk-sharing
agreements were introduced in the price negotiation. CONCLUSIONS: The poten-
tial pressure on theNHImay be even greater for growing financial gap in the future.
There are more efforts needed to seek the transparency in the listing and pricing
process for public good.
Health Care Use & Policy Studies – Health Care Research & Education
PHP69
HOW MUCH FOR A QALY IN KOREA
Kim Y1, Shin S1, Park S1, Song H1, Park J1, Bae E2, Ahn J1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Sangji
University, Wonju, Kangwon-do, South Korea
OBJECTIVES: Tomeasure willingness to pay (WTP) for a QALY in Korea.METHODS:
A survey questionnaire based on EQ-5D scenarios was developed tomeasure QALY
improvements in Korea. Double bounded dichotomous choice (DBDC) questions
along with an open question were used to elicit WTPs. Each person was asked for
four scenarios chosen from 3-item EQ-5D scenarios ( 1 QALY) and an additional
scenario with live in perfect health for 1 year or die now (1 QALY). The sameWTP
questions were also repeated for QALY improvements of a family member instead
of self. The questionnaire also includedquestions ondemographics, disease status,
and a visual analog scale (VAS)measure of each scenario presented. Consistency of
each respondent was checked by matching ranks of five scenarios between WTPs
andQALY improvements either by VAS or Korean EQ-5D tariff. Initial bids for DBDC
questionswere determined by the quintiles of pilot surveyWTPs. Survey questions
for each study were fine tuned though two focus group interview sessions per
study. A general population sample was interviewed face-to-face in 2010.
RESULTS:Of the total 1,017 persons surveyed, 933 persons passed consistency test.
For those who passed consistency and not in Medical Aids program, WTP for a
QALY calculated from the final open questions (after DBDC questions) was 19 mil-
lion KRW (approximately 16,000 USD). WTP for family member were consistently
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